Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads MRI scans to reveal hidden brain tumor types in children before surgery

NCT ID NCT07703605

Diagnosis Sponsor: Huashan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 24, 2026 · Updated 5 times

Summary

This study is developing an artificial intelligence (AI) system that can analyze standard MRI brain scans to determine the specific molecular subtype of a child's brain tumor before surgery. The research includes 1,400 children under 18 with suspected brain tumors, using both past and future patient data to train and test the AI. The goal is to see if the AI can accurately predict key tumor markers that currently require a tissue sample after surgery, which could help doctors plan treatment faster and more precisely.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an artificial intelligence (AI)-assisted diagnostic system that analyzes preoperative MRI scans to predict molecular subtypes of pediatric brain tumors
What this could lead to
If successful, this AI system could allow doctors to identify the specific molecular type of a child's brain tumor before surgery, enabling more personalized and timely treatment decisions without needing an invasive biopsy first.
What could go wrong
This is an observational study developing and validating the AI model, not a treatment trial. The AI's predictions may not be accurate enough for clinical use, and the results may not apply to all types of pediatric brain tumors or to other hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pediatric patients with suspected primary brain tumors who undergo first surgical treatment at participating centers and whose postoperative pathology confirms one of seven predefined tumor categories.

Ages

0 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age younger than 18 years at the time of index surgery. * Evaluated at a participating study center and scheduled for first surgical treatment of a suspected target pediatric brain tumor. * Preoperative brain MRI available before surgery, including at minimum T1-weighted, contrast-enhanced T1-weighted, T2-weighted, and FLAIR sequences in DICOM format; MRI preferably performed within 7 days before surgery and before biopsy or tumor-directed therapy. * Postoperative histopathology confirming one of the following target tumor categories: glioma, medulloblastoma, ependymoma, atypical teratoid/rhabdoid tumor, intracranial germ cell tumors, craniopharyngioma, or choroid plexus tumors. * For the prospective cohort, written informed consent provided by a parent or legal guardian, with child assent obtained when appropriate according to age, understanding, and local ethics requirements. Exclusion Criteria: * Postoperative pathology confirming a non-target tumor type. * Recurrent tumor, repeat surgery, or prior tumor-directed surgery before the index surgery. * Preoperative MRI of inadequate quality for analysis, including severe motion artifact, severe susceptibility/metal artifact, or incomplete field of view. * Prior biopsy, radiotherapy, chemotherapy, or other tumor-directed treatment before the index preoperative MRI that is judged to substantially affect imaging interpretation. * Concurrent malignant disease other than the target brain tumor. * Inability to comply with follow-up requirements in the prospective cohort, in the investigator's judgment, because of severe comorbidity or other practical limitations.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atypical teratoid/rhabdoid tumor are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atypical teratoid rhabdoid tumor central nervous system germ cell tumor choroid plexus neoplasm Choroid Plexus Neoplasms craniopharyngioma ependymoma glioma medulloblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Choroid plexus tumors Craniopharyngioma Ependymoma GLIOMA Medulloblastoma Pediatric brain tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.